Bhishamjit S. Chera

Bhishamjit S. Chera

Auto-generated profile, based on publicly available information

Bhishamjit S. Chera

Hollings Cancer Center, Medical University of South Carolina Charleston South Carolina USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Clinical Oncology
Verified
Journal Article
Open access
BCBhishamjit S. Chera
Bhishamjit S. Chera
SKSunil Kumar
Sunil Kumar
CSColette Shen
Colette Shen
RARobert Amdur
Robert Amdur
RDRoi Dagan
Roi Dagan
GGGaorav P. Gupta
Gaorav P. Gupta
PURPOSE: Plasma circulating tumor human papillomavirus DNA (ctHPVDNA) is a sensitive and specific biomarker of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). We investigated whether longitudinal monitoring of ctHPVDNA during post-treatment surveillance could accurately detect clinical disease recurrence.METHODS AND MATERIALS: A prospective biomarker clinical trial was conducted among patients with nonmetastatic HPV-associated (p16-positive) OPSCC. All patients were treated with curative-intent chemoradiotherapy (CRT). Patients underwent a 3-month post-CRT positron emission tomography/computed tomography scan and were thereafter clinically evaluated every 2-4 months (years 1-2), then every 6 months (years 3-5). Chest imaging was performed every 6 months. Blood specimens were collected every 6-9 months for analysis of plasma ctHPVDNA using a multianalyte digital polymerase chain reaction assay. The primary endpoint was to estimate the negative predictive value (NPV) and positive predictive value (PPV) of ctHPVDNA surveillance.RESULTS: Forty-five patients were enrolled, and 509 blood samples were analyzed. After a median follow-up time of 19.2 months (range, 14.1-30.6 months), 4 patients (9%) developed disease recurrence. Thirty-seven patients had undetectable ctHPVDNA at all post-treatment time points, and none developed recurrence (NPV, 100%; 95% CI, 91% to 100%). Eight patients developed a positive ctHPVDNA during post-treatment surveillance, 4 of whom were diagnosed with biopsy-proven recurrence. Four patients had 2 consecutively positive ctHPVDNA blood tests, all 4 of whom developed biopsy-proven recurrence. Two consecutively positive ctHPVDNA blood tests had a PPV of 100% (95% CI, 51% to 100%). Median lead time between ctHPVDNA positivity and biopsy-proven recurrence was 6.6 months (range, 3.3-12.9 months).CONCLUSION: Detection of ctHPVDNA in two consecutive plasma samples during post-treatment surveillance has high PPV and NPV for identifying disease recurrence in patients with HPV-associated oropharyngeal cancer and may facilitate earlier initiation of salvage therapy.

1 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BCBhishamjit S. Chera
Bhishamjit S. Chera
SKSunil Kumar
Sunil Kumar
BBBrian T. Beaty
Brian T. Beaty
DMDavid Marron
David Marron
SJStuart Jefferys
Stuart Jefferys
GGGaorav P. Gupta
Gaorav P. Gupta
Purpose: To identify a profile of circulating tumor human papilloma virus (HPV) DNA (ctHPVDNA) clearance kinetics that is associated with disease control after chemoradiotherapy (CRT) for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Experimental Design: A multi-institutional prospective biomarker trial was conducted in 103 patients with (i) p16-positive OPSCC, (ii) M0 disease, and (iii) receipt of definitive CRT. Blood specimens were collected at baseline, weekly during CRT, and at follow-up visits. Optimized multianalyte digital PCR assays were used to quantify ctHPVDNA (types 16/18/31/33/35) in plasma. A control cohort of 55 healthy volunteers and 60 patients with non–HPV-associated malignancy was also analyzed. Results: Baseline plasma ctHPVDNA had high specificity (97%) and high sensitivity (89%) for detecting newly diagnosed HPV-associated OPSCC. Pretreatment ctHPV16DNA copy number correlated with disease burden, tumor HPV copy number, and HPV integration status. We define a ctHPV16DNA favorable clearance profile as having high baseline copy number (>200 copies/mL) and >95% clearance of ctHPV16DNA by day 28 of CRT. Nineteen of 67 evaluable patients had a ctHPV16DNA favorable clearance profile, and none had persistent or recurrent regional disease after CRT. In contrast, patients with adverse clinical risk factors (T4 or >10 pack years) and an unfavorable ctHPV16DNA clearance profile had a 35% actuarial rate of persistent or recurrent regional disease after CRT (P = 0.0049). Conclusions: A rapid clearance profile of ctHPVDNA may predict likelihood of disease control in patients with HPV-associated OPSCC patients treated with definitive CRT and may be useful in selecting patients for deintensified therapy.

10 October 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BCBhishamjit S. Chera
Bhishamjit S. Chera
RARobert J. Amdur
Robert J. Amdur
RGRebecca Green
Rebecca Green
CSColette Shen
Colette Shen
GGGaorav Gupta
Gaorav Gupta
WMWilliam Mendenhall
William Mendenhall
PURPOSE: To report the results of a phase II clinical trial of de-intensified chemoradiotherapy for patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma. MATERIALS AND METHODS: Major inclusion criteria were (1) having American Joint Committee on Cancer (AJCC) 7th edition T0-T3, N0-N2c, M0 (AJCC 8th edition T0-T3, N0-N2, M0), (2) being p16 positive, and (3) reporting minimal or remote smoking history. Treatment was limited to 60 Gy intensity-modulated radiotherapy with concurrent intravenous cisplatin 30 mg/m2 once per week. Patients with T0-T2 N0-1 (AJCC 7th edition) did not receive chemotherapy. All patients had a 10- to 12-week post-treatment positron emission tomography/computed tomography to assess for neck dissection. The primary end point was 2-year progression-free survival. Secondary end points included 2-year local-regional control, distant metastasis-free survival and overall survival, and patient-reported outcomes (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire and the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events). RESULTS: One hundred fourteen patients were enrolled (median follow-up of 31.8 months), with 81% having a minimum follow-up of 2 years. Eighty percent of patients had 10 or fewer tobacco pack-years. Two-year local-regional control, distant metastasis-free survival, progression-free survival, and overall survival were as follows: 95%, 91%, 86%, and 95%, respectively. Mean pre- and 2-year post-treatment European Organisation for Research and Treatment of Cancer quality of life scores were as follows: global, 79/84 (lower worse); swallowing, 8/9 (higher worse); and dry mouth, 14/45 (higher worse). Mean pre- and 2-year post-treatment patient-reported outcomes version of the Common Terminology Criteria for Adverse Events scores (0 to 4 scale, higher worse) were as follows: swallowing, 0.5/0.7, and dry mouth, 0.4/1.3. Thirty-four percent of patients required a feeding tube (median, 10.5 weeks; none permanent). There were no grade 3 or higher late adverse events. CONCLUSION: Clinical outcomes with a de-intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent low-dose cisplatin are favorable in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma. Neither neoadjuvant chemotherapy nor routine surgery is needed to obtain favorable results with de-escalation.

1 September 2017 in Oral Oncology
Verified
Journal Article
Closed access
DMDominic H. Moon
Dominic H. Moon
SMSung Ho Moon
Sung Ho Moon
KWKyle Wang
Kyle Wang
MWMark C. Weissler
Mark C. Weissler
THTrevor G. Hackman
Trevor G. Hackman
BCBhishamjit S. Chera
Bhishamjit S. Chera

1 December 2015 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
BCBhishamjit S. Chera
Bhishamjit S. Chera
RARobert J. Amdur
Robert J. Amdur
JTJoel Tepper
Joel Tepper
BQBahjat Qaqish
Bahjat Qaqish
RGRebecca Green
Rebecca Green
WMWilliam Mendenhall
William Mendenhall

26 March 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
BCBhishamjit S. Chera
Bhishamjit S. Chera
RARobert J. Amdur
Robert J. Amdur
JTJoel E. Tepper
Joel E. Tepper
XTXianming Tan
Xianming Tan
JWJared Weiss
Jared Weiss
WMWilliam M. Mendenhall
William M. Mendenhall